People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug
Eli Lilly reports that participants with type 2 diabetes lost up to 60 pounds in a trial of its experimental weight-loss drug, retatrutide. The triple agonist compound delivered significant weight reduction and A1C reduction in patients with obesity and type 2 diabetes. Clinical testing recorded weight loss percentages reaching up to 21 percent and 25 percent in trial settings. Observers describe the experimental treatment as a high-water mark and a powerful obesity drug option for addressing metabolic conditions.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ People with Type 2 diabetes lost up to 60 pounds on Lilly's latest weight loss drug.
- ✓ Lilly's experimental drug cuts weight by 21% in a diabetes trial.
- ✓ Participants in trials lost up to 25% of their weight.
- ✓ Retatrutide is a triple agonist that delivered substantial weight loss and A1C reduction.
What changed
Eli Lilly released full phase 3 trial data for retatrutide, revealing substantial weight loss and A1C reduction for patients with type 2 diabetes.
Live updates
-
Eli Lilly Weight Loss Drug Trial Shows Substantial Results
Eli Lilly reports that participants with type 2 diabetes lost up to 60 pounds in a trial of its experimental weight-loss drug, retatrutide. The triple agonist compound delivered significant weight reduction and A1C reduction in patients with obesity and type 2 diabetes. Clinical testing recorded weight loss percentages reaching up to 21 percent and 25 percent in trial settings. Observers describe the experimental treatment as a high-water mark and a powerful obesity drug option for addressing metabolic conditions.
Why it matters
Pharmaceutical companies continue to advance next-generation therapeutics targeting obesity and associated metabolic conditions like type 2 diabetes. Eli Lilly's latest trial data positions its triple agonist compound competitively against existing therapies in the metabolic health sector. Full phase 3 trial results establish concrete benchmarks for efficacy in weight reduction and glycemic control.
What is confirmed
- People with Type 2 diabetes lost up to 60 pounds on Lilly's latest weight loss drug.
- Lilly's experimental drug cuts weight by 21% in a diabetes trial.
- Participants in trials lost up to 25% of their weight.
- Retatrutide is a triple agonist that delivered substantial weight loss and A1C reduction.
What to watch next
- Full phase 3 trial data evaluations by regulatory bodies
- Further announcements regarding commercial availability and pricing
confidence 100%Sources used for this update (15)
- Ars Technica — Most powerful obesity drug yet: People lost up to 25% of weight in trial
- The Guardian — ‘Godzilla’ of weight-loss drugs could provide other important health benefits
- Reuters — Lilly's experimental drug cuts weight by 21% in diabetes trial
- Scientific American — Blockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs
- NBC News — People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug
- Eli Lilly — Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
- Fierce Biotech — Lilly sets up next-gen obesity battle with full phase 3 retatrutide data
- Time Magazine — Eli Lilly’s Experimental Weight-Loss Drug Shows Promising Results
- dictionary.cambridge.org — PEOPLE | English meaning - Cambridge Dictionary
- nypost.com — people magazine | Latest News | New York Post
- pocketmags.com — People Magazine Subscriptions and 05-10-2026 Issue - Pocketmags
- www.dictionary.com — PEOPLE Definition & Meaning | Dictionary.com
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community